We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Ceramide d18:1/24:1 as a potential biomarker to differentiate obesity subtypes with unfavorable health outcomes.
- Authors
Yu, Baowen; Hu, Moran; Jiang, Wanzi; Ma, Yizhe; Ye, Jingya; Wu, Qinyi; Guo, Wen; Sun, Yan; Zhou, Min; Xu, Yiwen; Wu, Zhoulu; Wang, Yiwen; Lam, Sin Man; Shui, Guanghou; Gu, Jingyu; Li, John Zhong; Fu, Zhenzhen; Gong, Yingyun; Zhou, Hongwen
- Abstract
Background: The criteria for metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO) remain controversial. This research aimed to identify a potential biomarker to differentiate the subtypes of obesity. Methods: The study conducted a lipidomic evaluation of ceramide in the serum of 77 Chinese adults who had undergone hyperinsulinemic-euglycemic clamps. These adults were divided into three groups according to the clinical data: normal weight control group (N = 21), MHO (N = 20), and MUO (N = 36). Results: The serum Cer d18:1/24:1 level in the MHO group was lower than that in the MUO group. As the Cer d18:1/24:1 level increased, insulin sensitivity decreased, and the unfavorable parameters increased in parallel. Multivariate logistic regression analysis revealed that serum Cer d18:1/24:1 levels were independently correlated with MUO in obesity. Individuals with higher levels of Cer d18:1/24:1 also had an elevated risk of cardiovascular disease. Most ceramide subtype levels increased in obesity compared to normal-weight individuals, but the levels of serum Cer d18:0/18:0 and Cer d18:1/16:0 decreased in obesity. Conclusions: The relationships between ceramide subtypes and metabolic profiles might be heterogeneous in populations with different body weights. Cer d18:1/24:1 could be a biomarker that can be used to differentiate MUO from MHO, and to better predict who will develop unfavorable health outcomes among obese individuals. Trial registration: The First Affiliated Hospital of Nanjing Medical University's Institutional Review Board authorized this study protocol, and all participants provided written informed consent (2014-SR-003) prior to study entry.
- Subjects
CERAMIDES; LOGISTIC regression analysis; INSULIN sensitivity; INSTITUTIONAL review boards; BIOMARKERS
- Publication
Lipids in Health & Disease, 2023, Vol 22, Issue 1, p1
- ISSN
1476-511X
- Publication type
Article
- DOI
10.1186/s12944-023-01921-0